Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Controversial Dengue Drug Among Six Products To Get EMA Thumbs Up

Executive Summary

Dengvaxia, the dengue vaccine from Sanofi that was suspended in the Philippines last year, is among six new products to get a recommendation for marketing authorization from the European Medicines Agency this week.

Advertisement

Related Content

Anticancers, Orphans & The First CAR-Ts: New EU Drug Approvals In 2018
EU New Drug Approvals 2018: Anticancers, Orphans, The First CAR-Ts – And More
Latest Funding Moves Expand Keytruda Franchise In England
Keeping Track: FDA Starts November With A Bang
Lupin Gears For Europe Specialty Push With Orphan NaMuscla
Takhzyro Among Hopefuls For EU Approval Recommendation
Will Sanofi’s Dengvaxia Woes Spiral Beyond The Philippines?
Sanofi's Dengue Vaccine Gets WHO Backing In People Previously Infected

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS124102

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel